Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

2KEYNOTE-045 (all population), 2017 KEYNOTE-045 (PDL1 CPS >10%), 20173IMvigor-211 (PDL1>5%), 2018 IMvigor-211 (PDL1>1%), 2018 IMvigor-211 (all population), 2018atezolizumab alone vs. pembrolizumab alone 1.24 [0.99; 1.55]1.24 [0.99;1.55]atezolizumab alone vs. pembrolizumab alone 1.24 [0.99; 1.55]atezolizumab alone vs. Standard of Care (SoC) atezolizumab alone better 0.86 [0.77; 0.96]0.86 [0.77;0.96]atezolizumab alone vs. Standard of Care (SoC) atezolizumab alone better 0.86 [0.77; 0.96]pembrolizumab alone vs. atezolizumab alone 0.81 [0.65; 1.01]0.81 [0.65;1.01]pembrolizumab alone vs. atezolizumab alone 0.81 [0.65; 1.01]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.69 [0.57; 0.84]0.69 [0.57;0.84]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.69 [0.57; 0.84]Standard of Care (SoC) vs. atezolizumab alone atezolizumab alone better 1.16 [1.04; 1.30]1.16 [1.04;1.30]Standard of Care (SoC) vs. atezolizumab alone atezolizumab alone better 1.16 [1.04; 1.30]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.44 [1.19; 1.75]1.44 [1.19;1.75]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.44 [1.19; 1.75]Standard of Care (SoC)pembrolizumab aloneatezolizumab alonedirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)pembrolizumab aloneatezolizumab alone
Standard of Care (SoC)---1.44
1.19; 1.75		1.16
1.04; 1.30
pembrolizumab alone0.69
0.57; 0.84		---0.81
0.65; 1.01
atezolizumab alone0.86
0.77; 0.96		1.24
0.99; 1.55		---

pathologies: 290,155,154 - treatments: 361 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons